

Company


iHeart Japan Corporation

Presenter

Kenji
Kakuta



IHJ-301: allogeneic iPSC-derived
multi-layered cardiac cell sheets
for severe heart failure



potential market size:
> USD 300 million in JP

clinical study in 2019
clinical trial in 2020

WANTED

- ✓ co-development partner
- ✓ USD 10 million to complete the clinical trial